Improving the efficacy of Cyclooxegenase-2 inhibitors in the management of oral cancer: Insights into the implementation of nanotechnology and mucoadhesion
Authors:
- Aya A. MabroukAMAya A. Mabrouk
- Mina Ibrahim TadrosMTMina Ibrahim Tadros
- Wessam M. El-RefaieWEWessam M. El-Refaie
- 1 February 2021
- journal article
- review article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 61
Abstract
No abstract availableKeywords
This publication has 119 references indexed in Scilit:
- Over-expression of COX-2 mRNA in colorectal cancerBMC Gastroenterology, 2014
- Liposome: classification, preparation, and applicationsDiscover Nano, 2013
- The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheresInternational Journal of Nanomedicine, 2011
- Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriersJournal of Controlled Release, 2010
- Targeted nanodelivery of drugs and diagnosticsNano Today, 2010
- Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsionJournal of Nanobiotechnology, 2008
- Chemopreventive Effect of Celecoxib in Oral Precancers and CancersThe Laryngoscope, 2006
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000